Programme

Take a look at the interactive multi-stream agenda for HPE LIVE 2017 below. For more information on what will be discussed in each individual session, simply click on the stream title at the top of the agenda. If you would like more details on the speaker, their biography can be viewed by clicking on that speakers name.

To navigate back to the full agenda click on the grey “Full Agenda” square on the top left.

Delegates are welcome to move freely between the streams during the day.

09:00

Registration Opens

09:40

Chair's Open

Chair's Open

Chair's Open

Chair's Open

Chair's Open

10:00

Biosimilars an NHS perspective

  • Margaret Dolan, Specialist Procurement Pharmacist, NHS Commercial Solutions

Saving lives and strokes with appropriate oral anticoagulation in atrial fibrillation

  • Liz Corteville, Medicines Optimisation Locality Lead Pharmacist, West Hampshire CCG

The changing landscape of eczema treatment

  • Christine Clark, Editor of Hospital Pharmacy Europe, freelance medical writer and pharmacy consultant specialising in dermatology

Liver disease: What can community services do to reduce its burden?

  • Jeremy Thompson, GP and Clinical Director, Bevan Healthcare; British Liver Trust/RCGP Clinical Champion for Liver Disease

Managing chemotherapy electronically from prescription to patient 

  • Brid Ryan, Aseptic Compounding Service Manager, Mater Misericordiae University Hospital, Dublin, Ireland and Honorary Clinical Lecturer, Royal College of Surgeons Ireland
10:40

Coffee Break

11:10

Industry session supported by C A R D i O M E

Managing heart failure patients in hospital

  • Joanne Bateman, Lead Cardiology Pharmacist, The Countess of Chester NHS Trust

How pharmacists can improve outcomes for patients with psoriasis

  • Rod Tucker, Community Pharmacist and Research Associate, Robert Gordon University

Current thinking on inflammatory bowel disease

  • Anja St. Clair Jones, Consultant Pharmacist Gastroenterology, Brighton and Sussex University Hospitals NHS Trust

Industry session to be confirmed

11:55

Antimicrobial stewardship in practice

Industry Session Supported by Daiichi-Sankyo

Recommending the correct emollient

  • Ibrar Ahmed, Pharmacist and Commissioner, NHS Leeds South and East CCG

Proposed topic: Gluten free - where are we now?

Safe compounding of hazardous drugs

  • John Landers, Medicines Assurance and Aseptic Services Manager Pharmacy Department, Salford Royal Hospital NHS Foundation Trust
12:35

Lunch

13:25

Shortages of Medicines

  • Jane Nicholson, Executive Director of European Industrial Pharmacists Group

Best practice in treating stroke

  • Derek Taylor, Assistant Director of Pharmacy for Governance and Risk, Royal Liverpool and Broadgreen University Hospitals NHS Trust

Industry session to be confirmed

Recent advances in irritable bowel syndrome

  • Adam Farmer, Honorary Consultant Gastroenterologist & Lecturer, Barts & the London School of Medicine, Queen Mary University of London

A test protocol to assess the efficacy of closed system transfer devices (CSTDs) – an interventions to further reduce occupational exposure in the hospital pharmacy and ward setting

  • Alan Wilkinson, Chief Executive Officer, Biopharma Stability Testing Laboratory (BSTL)
14:10

Improving effective anticoagulant therapy in VTE Care

  • Sharron Gordon, Pharmacist Consultant Anticoagulation, Managing Director Sharron Gordon Ltd

Better integrated care for diabetes patients: Getting the right care at the right time

  • Hannah Beba, Senior Pharmacist for Diabetes and Endocrinology, County Durham and Darlington NHS Foundation Trust

Proposed title: Critical issues in Rheumatology 2017

Industry session to be confirmed

Safe administration of hazardous drugs

  • Lesley Sheen, Nurse Consultant Chemotherapy, Colchester Hospital University NHS Foundation Trust
14:50

Coffee break

15:15

Medication safety and opioids: safer by design

  • Alice Osborne, Consultant pharmacist, medication safety, Guy’s and St Thomas’ Hospital

New drugs to treat diabetes

  • Sallianne Kavanagh, Lead Clinical Pharmacist Diabetes and Endocrinology, Sheffield Teaching Hospitals NHSFT

Personalised medicine for the rheumatology patient

  • Hilary McKee, Consultant Pharmacist, Northern Health and Social Care Trust

Understanding liver disease

  • Valerie Ross, Lead Pharmacist Hepatology, Barts Health NHS Trust

mAbs: Improving care and protecting staff

  • Ian Rudd, Director of Pharmacy, NHS Highland
16:00

To Scan or not to Scan   – Background to the EU Falsified Medicines Directive  (FMD)

  • Aileen Bryson, Practice and Policy Lead at Royal Pharmaceutical Society Scotland

Diabetes and ethnicity

  • Lubna Kerr, Senior Hospital Pharmacy Practitioner, NHS Lothian

Biologic therapy in rheumatology

Hepatitis C: The yellow brick road to elimination

  • Sital Shah, Senior hepatology pharmacist, King’s College Hospital

Dose banding: Making it work in practice

  • Richard Nuttall, Electronic prescribing pharmacist, Royal Marsden NHS Foundation Trust
16:40

Conference Ends

09:00

Registration Opens

09:40

Chair's Open

10:00

Biosimilars an NHS perspective

  • What are the opportunities/challenges.
  • Stakeholder engagement.
  • Analysis of uptake.
Speaker(s):
  • Margaret Dolan, Specialist Procurement Pharmacist, NHS Commercial Solutions, ,
10:40

Coffee Break

11:10

Industry session supported by C A R D i O M E

11:55

Antimicrobial stewardship in practice

  • Antimicrobial stewardship is a key intervention to address the escalating global threat of antimicrobial resistance.
  • Many hospitals have established antimicrobial stewardship programmes and pharmacists have an important role to play in both leading and supporting this work.
  • A range of stewardship interventions including surveillance of antimicrobial use, quality improvement initiatives and education of healthcare staff can be used to optimise prescribing practice.
Speaker(s):
12:35

Lunch

13:25

Shortages of Medicines

  • The main reasons for medicines shortages and where in the supply chain they occur.
  • What has been done to engage manufacturers, wholesalers, parallel traders and government representatives with the problems of community and hospital pharmacists.
  • How  to reduce medicines shortages and minimise the adverse effect of shortages on patients.
Speaker(s):
  • Jane Nicholson, Executive Director of European Industrial Pharmacists Group, Industrial Pharmacists Group, Slough
14:10

Improving effective anticoagulant therapy in VTE Care

  • Putting guidelines into practice.
  • Managing challenging patient populations.
  • Making care safe and streamlined.
Speaker(s):
  • Sharron Gordon, Pharmacist Consultant Anticoagulation, Managing Director Sharron Gordon Ltd, , Easton, Hampshire
14:50

Coffee break

15:15

Medication safety and opioids: safer by design

  • The session will include
  • A designing for safety approach to safer use of opioid patches
  • Use of electronic systems to reduce medication formulation errors
  • What we have learned during attempts to spread practice
Speaker(s):
  • Alice Osborne, Consultant pharmacist, medication safety, Guy’s and St Thomas’ Hospital, , London
16:00

To Scan or not to Scan   – Background to the EU Falsified Medicines Directive  (FMD)

  • FMD – The  basics
  • The clock is ticking
  • Brexit and the FMD
Speaker(s):
  • Aileen Bryson, Practice and Policy Lead at Royal Pharmaceutical Society Scotland, ,
16:40

Conference Ends

09:00

Registration Opens

09:40

Chair's Open

10:00

Saving lives and strokes with appropriate oral anticoagulation in atrial fibrillation

  • Stopping the use of aspirin (or other antiplatelet monotherapy) for AF-stroke prevention in high-risk patients.
  • Optimising warfarin control in AF-related stroke prevention.
  • Initiating/changing to a DOAC in high-risk patients.
Speaker(s):
  • Liz Corteville, Medicines Optimisation Locality Lead Pharmacist, West Hampshire CCG, ,
10:40

Coffee Break

11:10

Managing heart failure patients in hospital

  • Overview of the management of heart failure.
  • Considerations in complex patients.
  • What’s new in heart failure?
Speaker(s):
  • Joanne Bateman, Lead Cardiology Pharmacist, The Countess of Chester NHS Trust, , Chester
11:55

Industry Session Supported by Daiichi-Sankyo

12:35

Lunch

13:25

Best practice in treating stroke

  • Outline best practice in the acute management of stroke patients.
  • Discuss the evidence base of secondary preventative medicines post-stroke.
  • Identify the role of pharmacy in the acute and outgoing management of stroke patients.
Speaker(s):
  • Derek Taylor, Assistant Director of Pharmacy for Governance and Risk, Royal Liverpool and Broadgreen University Hospitals NHS Trust, , Liverpool
14:10

Better integrated care for diabetes patients: Getting the right care at the right time

  • The concept of ‘case loading’ within the hospital.
  • Development of outreach services from the hospital.
  • Development of ‘specialist interest’ in diabetes in primary care and community pharmacy.
Speaker(s):
  • Hannah Beba, Senior Pharmacist for Diabetes and Endocrinology, County Durham and Darlington NHS Foundation Trust, , County Durham and Darlington
14:50

Coffee break

15:15

New drugs to treat diabetes

  • Introduction to the newer agents for the management of Type 2 Diabetes
  • Brief review of the evidence to support use of the new agents
  • Place in therapy when considering the application of NICE guidance
Speaker(s):
  • Sallianne Kavanagh, Lead Clinical Pharmacist Diabetes and Endocrinology, Sheffield Teaching Hospitals NHSFT, ,
16:00

Diabetes and ethnicity

  • Diabetes in South Asians.
  • Understanding cultural issues.
  • Model of care.
  • Stigma and prejudice.
Speaker(s):
  • Lubna Kerr, Senior Hospital Pharmacy Practitioner, NHS Lothian, , Edinburgh
16:40

Conference Ends

09:00

Registration Opens

09:40

Chair's Open

10:00

The changing landscape of eczema treatment

  • Eczema (atopic dermatitis) is associated with a defective skin barrier and immune dysfunction.
  • Inflammatory processes that drive eczema and new targets for therapeutic intervention.
  • How ‘traditional’ and new treatments such as dupilumab and crisaborole fit into the picture.
  • What this means in practice for treatment pathways and patient care.
Speaker(s):
  • Christine Clark, Editor of Hospital Pharmacy Europe, freelance medical writer and pharmacy consultant specialising in dermatology, , Lancashire
10:40

Coffee Break

11:10

How pharmacists can improve outcomes for patients with psoriasis

  • Psoriasis is a complex, multifactorial immune-mediated inflammatory condition.
  • Patients with psoriasis want, but rarely receive advice and support on how to use treatments.
  • Pharmacist-led educational advice can have a potential important impact on patient-related disease outcomes.
Speaker(s):
  • Rod Tucker, Community Pharmacist and Research Associate, Robert Gordon University, , Aberdeen, Scotland
11:55

Recommending the correct emollient

Speaker(s):
  • Ibrar Ahmed, Pharmacist and Commissioner, NHS Leeds South and East CCG, ,
12:35

Lunch

13:25

Industry session to be confirmed

14:10

Proposed title: Critical issues in Rheumatology 2017

14:50

Coffee break

15:15

Personalised medicine for the rheumatology patient

  • Predictors for severity of disease.
  • Choice of drug.
  • Complicating factors.
Speaker(s):
  • Hilary McKee, Consultant Pharmacist, Northern Health and Social Care Trust, , Antirm, Northern Ireland
16:00

Biologic therapy in rheumatology

  • Biologic therapy pathways.
  • Implementing biosimilars.
  • Biologic therapy dose reduction.
Speaker(s):
16:40

Conference Ends

09:00

Registration Opens

09:40

Chair's Open

10:00

Liver disease: What can community services do to reduce its burden?

  • Morbidity and mortality due to liver disease are rising.
  • Up to 90% of liver disease is preventable.
  • Community services have a major role to play in its prevention.
Speaker(s):
  • Jeremy Thompson, GP and Clinical Director, Bevan Healthcare; British Liver Trust/RCGP Clinical Champion for Liver Disease, , Middlesbrough
10:40

Coffee Break

11:10

Current thinking on inflammatory bowel disease

Speaker(s):
  • Anja St. Clair Jones, Consultant Pharmacist Gastroenterology, Brighton and Sussex University Hospitals NHS Trust, , Sussex
11:55

Proposed topic: Gluten free - where are we now?

12:35

Lunch

13:25

Recent advances in irritable bowel syndrome

  • Irritable bowel syndrome is a chronic disorder characterised by abdominal pain coupled with a change in the form and/or frequency of stool. The predominant stool pattern can help subdivide the disorder into diarrhoea or constipation predominant or alternating IBS.
  • It is a common disorder, afflicting approximately 5% of the UK adult population.
  • Treatment is multifaceted but includes patient education.
  • New pharmacological interventions are developing and beginning to positively impact on patient outcomes.
Speaker(s):
  • Adam Farmer, Honorary Consultant Gastroenterologist & Lecturer, Barts & the London School of Medicine, Queen Mary University of London, , London
14:10

Industry session to be confirmed

14:50

Coffee break

15:15

Understanding liver disease

Speaker(s):
  • Valerie Ross, Lead Pharmacist Hepatology, Barts Health NHS Trust, ,
16:00

Hepatitis C: The yellow brick road to elimination

  • Updates in treatment options.
  • Challenges in testing and case finding.
  • Delivery of treatment in the community.
Speaker(s):
  • Sital Shah, Senior hepatology pharmacist, King’s College Hospital, , London
16:40

Conference Ends

09:00

Registration Opens

09:40

Chair's Open

10:00

Managing chemotherapy electronically from prescription to patient 

  • The experience of implementing integrated prescribing, manufacture and administration of chemotherapy to ensure a closed loop system.
  • Benefits and challenges encountered.
  • How gravimetric manufacture of chemotherapy contributes to an aseptic compounding service.
Speaker(s):
  • Brid Ryan, Aseptic Compounding Service Manager, Mater Misericordiae University Hospital, Dublin, Ireland and Honorary Clinical Lecturer, Royal College of Surgeons Ireland, , Dublin
10:40

Coffee Break

11:10

Industry session to be confirmed

11:55

Safe compounding of hazardous drugs

  • What are the risks to operators when compounding cytotoxics and who is at risk?
  • How can we practically manage these risks?
  • What monitoring should we be undertaking as part of the risk management process?
Speaker(s):
  • John Landers, Medicines Assurance and Aseptic Services Manager Pharmacy Department, Salford Royal Hospital NHS Foundation Trust, , Salford
12:35

Lunch

13:25

A test protocol to assess the efficacy of closed system transfer devices (CSTDs) – an interventions to further reduce occupational exposure in the hospital pharmacy and ward setting

  •  CSTDs.
  • Test protocol, occupational health and safety.
  • Cytotoxic drugs.
Speaker(s):
  • Alan Wilkinson, Chief Executive Officer, Biopharma Stability Testing Laboratory (BSTL), ,
14:10

Safe administration of hazardous drugs

  • What are the risks to operators when compounding cytotoxics and who is at risk?
  • How can we practically manage these risks?
  • What monitoring should we be undertaking as part of the risk management process?
Speaker(s):
  • Lesley Sheen, Nurse Consultant Chemotherapy, Colchester Hospital University NHS Foundation Trust, , Colchester
14:50

Coffee break

15:15

mAbs: Improving care and protecting staff

NHS Highland has used closed system devices to prepare monoclonal antibodies to

  • Improve the efficiency of its service to patients and staff
  • Improve the cost effectiveness of its service
  • Minimise risk to staff
Speaker(s):
  • Ian Rudd, Director of Pharmacy, NHS Highland, , Scotland
16:00

Dose banding: Making it work in practice

  • How do we dose band / methods used.
  • Challenges of dose banding.
  • Where to next?
Speaker(s):
  • Richard Nuttall, Electronic prescribing pharmacist, Royal Marsden NHS Foundation Trust, , London
16:40

Conference Ends



*Please note this programme is subject to change.

**We would like to thank our exhibitors for supporting this meeting, which includes a number of pharmaceutical companies. Unless stated in the programme, they have had no input into the agenda, speaker selection or content.